Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4+ and CD8+ memory formation

Immunology

Volumn 145, Issue 4, 2015, Pages 558-569

  Schmied, Sabine ^a   Gostick, Emma ^b   Price, David A ^b   Abken, Hinrich ^c,d   Assenmacher, Mario ^a   Richter, Anne ^a  

^a MILTENYI BIOTEC GMBH   (Germany)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Antigen specific T cells; Self antigen; Tumour associated antigen; Wilms' tumour 1 protein

Indexed keywords

CD137 ANTIGEN; CD40 LIGAND; HLA ANTIGEN CLASS 1; WT1 PROTEIN; TUMOR ANTIGEN; WT1 PROTEIN, HUMAN;

ARTICLE; BLOOD DONOR; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL LINEAGE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENRICHMENT CULTURE; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MEMORY T LYMPHOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; T LYMPHOCYTE SUBPOPULATION; FEMALE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MALE;

ANTIGENS, CD137; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; MALE; WT1 PROTEINS;

EID: 84936190839     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12472     Document Type: Article

References (42)

1. Cheever MA, Allison JP, Ferris AS et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37.
2. Rezvani K, Yong AS, Savani BN et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood 2007; 110:1924-32.
3. + T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT. Bone Marrow Transplant 2009; 43:399-410.
4. Tyler EM, Jungbluth AA, O'Reilly RJ, Koehne G. WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions. Blood 2013; 121:308-17.
5. Sloand EM, Melenhorst JJ, Tucker ZC et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011; 117:2691-9.
6. + T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood 2003; 102:2892-900.
7. Rezvani K, Brenchley JM, Price DA et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005; 11:8799-807.
8. + T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190:705-15.
9. Zippelius A, Pittet MJ, Batard P et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002; 195:485-94.
10. + T cells reveals conserved precursor frequencies. Blood 2010; 115:3718-25.
11. + memory-phenotype T cells are abundant in unexposed adults. Immunity 2013; 38:373-83.
12. Bacher P, Schink C, Teutschbein J, Kniemeyer O, Assenmacher M, Brakhage AA, Scheffold A. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J Immunol 2013; 190:3967-76.
13. + T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007; 110:201-10.
14. + T cell populations specific for persistent DNA viruses. J Exp Med 2005; 202:1349-61.
15. + T cells without the need to know epitope specificities. Cytometry 2008; 73:1043-9.
16. Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51:99-107.
17. Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ. Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 2002; 100:3835-7.
18. + T lymphocyte activation in response to therapeutic manipulation of virus load. Eur J Immunol 2001; 31:1115-21.
19. + T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia 2011; 25:1587-97.
20. + T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11:1118-24.
21. + T lymphocytes with cellular maturation. J Exp Med 2006; 203:2865-77.
22. + T cells with peptide-major histocompatibility complex class I tetramers. Cytometry 2008; 73:1001-9.
23. + T cells correlates with immunodominance in the human memory repertoire. J Immunol 2012; 188:2537-44.
24. + T cell repertoire in unimmunized mice includes memory phenotype cells bearing markers of homeostatic expansion. J Exp Med 2009; 206:435-48.
25. Lee JY, Hamilton SE, Akue AD, Hogquist KA, Jameson SC. Virtual memory CD8 T cells display unique functional properties. Proc Natl Acad Sci USA 2013; 110:13498-503.
26. + T cells and dendritic cells in vivo. J Exp Med 2006; 203:505-11.
27. Tang Q, Adams JY, Tooley AJ et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 2006; 7:83-92.
28. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and Influenza A virus determinant-specific cytotoxic T cells. J Virol 2001; 75:11392-400.
29. + T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis. J Clin Invest 2005; 115:3602-12.
30. Wooldridge L, Ekeruche-Makinde J, van den Berg HA et al. A single autoimmune T cell receptor recognizes more than a million different peptides. J Biol Chem 2012; 287:1168-77.
31. Welsh RM, Che JW, Brehm MA, Selin LK. Heterologous immunity between viruses. Immunol Rev 2010; 235:244-66.
32. Wilson DB, Wilson DH, Schroder K, Pinilla C, Blondelle S, Houghten RA, Garcia KC. Specificity and degeneracy of T cells. Mol Immunol 2004; 40:1047-55.
33. Pinto S, Sommermeyer D, Michel C, Wilde S, Schendel D, Uckert W, Blankenstein T, Kyewski B. Mis-initiation of intrathymic MART-1 transcription and biased TCR usage explain the high frequency of MART-1-specific T cells. Eur J Immunol 2014; 44:2811-21.
34. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol 2003; 21:139-76.
35. + T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013; 5:174ra27.
36. Van Driessche A, Berneman ZN, Van Tendeloo VF. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist 2012; 17:250-9.
37. Uttenthal B, Martinez-Davila I, Ivey A et al. Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses. Br J Haematol 2014; 164:366-75.
38. + T cells in myeloid malignancies. Haematologica 2011; 96:432-40.
39. Keilholz U, Letsch A, Busse A et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113:6541-8.
40. Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116:171-9.
41. Krug LM, Dao T, Brown AB et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010; 59:1467-79.
42. Van Tendeloo VF, Van de Velde A, Van Driessche A et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107:13824-9.